XRCC2 and acute myeloid leukemia: Mutations in FANCA were the most prevalent (0.46%), followed by BRCA1 (0.37%) and XRCC2 (0.34%) in AML patients, while FANCA mutation rate was the highest in MDS patients (0.29%).